Journal of Clinical Oncology

Vol. 43, Issue 12 Issue 12 2025
15
Articles

Articles in this Issue

Erratum: Phase II Study of Acalabrutinib, Venetoclax, and Obinutuzumab in a Treatment-Naïve Chronic Lymphocytic Leukemia Population Enriched for High-Risk Disease

Matthew S. Davids, Christine E. Ryan, Benjamin L. Lampson et al. Apr 20, 2025 pp. 1521-1522 10.1200/jco-25-00466

Fertility Preservation in People With Cancer: ASCO Guideline Update

H. Irene Su, Christina Lacchetti, Joseph Letourneau et al. Apr 20, 2025 pp. 1488-1515 10.1200/jco-24-02782

ASCO Guidelines provide recommendations with comprehensive review and analyses of the relevant literature for each recommendation, following the guideline development process as outlined in the...

Reply to: Glofitamab for the Treatment of Relapsed/Refractory Mantle Cell Lymphoma

Tycel Jovelle Phillips Apr 20, 2025 pp. 1519-1520 10.1200/jco-25-00088

Surrogate End Points for Overall Survival in Neoadjuvant Randomized Clinical Trials for Early Breast Cancer

Fabio Conforti, Valentina Nekljudova, Isabella Sala et al. Apr 20, 2025 pp. 1441-1452 10.1200/jco-24-01360

PURPOSE To assess trial-level surrogacy value for overall survival (OS) of the pathologic complete response (pCR) and invasive disease-free survival (iDFS) in randomized clinical trials (R...

Machine Learning to Predict Mortality in Older Patients With Cancer: Development and External Validation of the Geriatric Cancer Scoring System Using Two Large French Cohorts

Etienne Audureau, Pierre Soubeyran, Claudia Martinez-Tapia et al. Apr 20, 2025 pp. 1429-1440 10.1200/jco.24.00117

PURPOSE Establishing an accurate prognosis remains challenging in older patients with cancer because of the population's heterogeneity and the current predictive models' reduced ability to...

Glofitamab for the Treatment of Relapsed/Refractory Mantle Cell Lymphoma

Yutaka Shimazu, Yayoi Shimazu Apr 20, 2025 pp. 1519-1519 10.1200/jco-24-02259

Baseline Liquid Biopsy in Relation to Tissue-Based Parameters in Metastatic Colorectal Cancer: Results From the Randomized FIRE-4 (AIO-KRK-0114) Study

Sebastian Stintzing, Susanne Klein-Scory, Ludwig Fischer von Weikersthal et al. Apr 20, 2025 pp. 1463-1473 10.1200/jco.24.01174

PURPOSE The FIRE-4 study randomly assigned patients with first-line RAS wild-type ( RAS...

Neoadjuvant Nivolumab Plus Ipilimumab Versus Chemotherapy in Resectable Lung Cancer

Mark M. Awad, Patrick M. Forde, Nicolas Girard et al. Apr 20, 2025 pp. 1453-1462 10.1200/jco-24-02239

PURPOSE Neoadjuvant immune checkpoint blockade with nivolumab plus ipilimumab improves overall survival (OS) in non–small cell lung cancer (NSCLC); however, randomized data for res...

I Hope So Too

Richard E. Leiter Apr 20, 2025 pp. 1516-1517 10.1200/jco-24-02346

Even in our most difficult moments as clinicians, we can find space to hope with our patients, if we look for it. Dr Richard Leiter tells the powerful story of caring for a young man dying of GVHD.

Rethinking the Path to Bladder Cancer Staging: Can Magnetic Resonance Imaging Speed Up Time to Receipt of Therapy in Patients With Muscle-Invasive Bladder Cancer?

Ashish M. Kamat, Paul Frankel Apr 20, 2025 pp. 1401-1403 10.1200/jco-24-02482

Missed Opportunity for Sotorasib Dose Optimization

Garth W. Strohbehn, Jill Feldman, Sanjay Popat et al. Apr 20, 2025 pp. 1518-1519 10.1200/jco-24-02468

Erratum: Paclitaxel, Ifosfamide, and Cisplatin as Initial Salvage Chemotherapy for Germ Cell Tumors: Long-Term Follow-Up and Outcomes for Favorable- and Unfavorable-Risk Disease

Jack P. Gleeson, Andrea Knezevic, Maria Bromberg et al. Apr 20, 2025 pp. 1521-1521 10.1200/jco-25-00475

Data, Models, and Visuals: How Data Science Methods Can Augment (Geriatric) Oncology Research

Erika Ramsdale, Supriya Mohile Apr 20, 2025 pp. 1404-1407 10.1200/jco-25-00053

Olaparib as Treatment Versus Nonplatinum Chemotherapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer: Phase III SOLO3 Study Final Overall Survival Results

Giovanni Scambia, Ricardo Villalobos Valencia, Nicoletta Colombo et al. Apr 20, 2025 pp. 1408-1416 10.1200/jco.24.00933

Olaparib treatment significantly improved objective response rate (primary end point) and progression-free survival versus nonplatinum chemotherapy in patients with BRCA-mutated platinum-sensitive rel...

Postoperative Radiotherapy ± Cetuximab for Intermediate-Risk Head and Neck Cancer

Pedro A. Torres-Saavedra, Stephen L. Breen, Jason W. Chan et al. Apr 20, 2025 pp. 1474-1487 10.1200/jco-24-01829

PURPOSE Radiotherapy (RT)/cetuximab (C) demonstrated superiority over RT alone for locally advanced squamous head and neck cancer. We tested this in completely resected, intermediate-risk...

All Issues

Journal Info

Publisher Lippincott Williams & Wilkins
ISSN 0732-183X
E-ISSN 1527-7755
Subject Health Sciences
Language English
View Full Journal Page